Incyte- INCB39110 – Another JAK-Fruit in INCY’s Basket
Positive results from the PhII trial of INCB39110 (PhII, selective oral JAK 1 inhibitor, unpartnered) in pts with chronic plaque psoriasis who had inadequate response to prior topical therapies demonstrated proof-of-concept (PoC) in Chronic Plaque Psoriasis. At European Academy of Dermatology and Venereology (EADV) 2013, INCY presented exploratory efficacy analyses which suggested that efficacy was approximately equal in pts with >10% body surface area involvement and in pts with less 10% body surface area involvement prior to treatment. Data is comparable to PFE’s JAK1/3 inhibitor, Tofacitinib (Launched for RA – Xeljanz) and in light of current competition in plaque psoriasis market. For more detail, please read our report on INCY, released on Oct. 3, 2013, titled, 'INCB39110 – Another JAK-Fruit in INCY’s Basket'
More Publications
Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars
US$ 2,500.00
January 2014
113 pages
INCYTE: Cheers for INCY - JAKAVI Receives CHMP Nod!
US$ 90.00
April 2012
2 pages
Incyte Corporation Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
US$ 499.00
September 2026
50 pages
A Big BiTE - ALL Next!
US$ 140.00
July 2011
5 pages
ASTRAZENECA - First in class Forxiga (dapagliflozin) approved in Europe – Diabetes portfolio may heal AstraZeneca’s pains
US$ 90.00
November 2012
3 pages
